4-tert-butyl-N-(3-hydroxyl-phenyl)-benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-tert-butyl-N-(3-hydroxyl-phenyl)-benzenesulfonamide
• 英文别名: 4-tert-butyl-N-(3-hydroxylphenyl)benzenesulfonamide；4-tert-butyl-N-(3-hydroxyphenyl)benzenesulfonamide
• 化学式: C₁₆H₁₉NO₃S
• 分子量: 305.398
• InChiKey: PFOZVVVJWABLDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对叔丁基苯磺酰氯 、 3-氨基苯酚 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以5.7%的产率得到4-tert-butyl-N-(3-hydroxyl-phenyl)-benzenesulfonamide
  参考文献：
  名称：

  小分子磺酰胺在软骨分化和关节软骨修复中的潜在治疗应用

  摘要：

  关节软骨受损的修复是再生医学的长期目标。间充质干细胞（MSCs）的软骨细胞特异性分化可能是修复受损软骨的有效手段。我们确定了磺酰胺作为促进人脂肪来源的MSC（hASCs）的特定软骨分化的试剂的小分子6。与其他由各种定义成分组成的软骨分化培养基不同，在本研究中，仅将化合物6添加到培养基中就足以诱导软骨形成。在动物骨关节炎模型中，小分子6和6经治疗的hASC显示出受损的关节软骨恢复增强。这项工作为小分子诱导的MSC分化提供了新的见识，并为关节软骨损伤提供了潜在的新治疗方法。

  DOI：

  10.1016/j.bmcl.2016.08.069

文献信息

• PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS
  申请人：Kwon Ho Jeong

  公开号：US20140315947A1

  公开（公告）日：2014-10-23

  The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.

  本发明涉及一种用于抑制血管生成的药物组合物以及一种新型磺酰胺衍生物化合物，该化合物可用于预防或治疗与血管生成相关的疾病或疾病。由于本发明药物组合物中所使用的活性成分化合物特异地结合到UQCRB并抑制其生物功能，不会诱导凋亡并抑制血管生成反应。因此，本发明药物组合物中所使用的活性成分化合物可以作为一种有效且安全的抑制血管生成的药剂。
• Use of Compounds for Inducing Differentiation of Mesenchymal Stem Cells to Chondrocytes
  申请人：Hwang Ki Chul

  公开号：US20130236969A1

  公开（公告）日：2013-09-12

  Use of a compound of Formula 1 for inducing differentiation of mesenchymal stem cells to chondrocytes, and a pharmaceutical composition for treating a cartilage disease, which includes chondrocytes in which differentiation from mesenchymal stem cells is induced by the compound of Formula 1, are provided. Differentiation of the mesenchymal stem cells treated with the compound of Formula 1 to chondrocytes is specifically induced, and thus the compound can be used to effectively treat a cartilage disease such as arthritis, cartilage damage, and a cartilage defect.

  提供一种使用公式1的化合物诱导间充质干细胞向软骨细胞分化的方法，以及用于治疗软骨疾病的制药组合物，其中包括由公式1的化合物诱导的间充质干细胞分化成的软骨细胞。经过公式1化合物处理的间充质干细胞被特异性地诱导分化成软骨细胞，因此该化合物可有效治疗软骨疾病，例如关节炎，软骨损伤和软骨缺陷。
• USE OF COMPOUNDS FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO CHONDROCYTES
  申请人：MSP Co., Ltd

  公开号：EP3056198A2

  公开（公告）日：2016-08-17

  Use of a compound of Formula 1 for inducing differentiation of mesenchymal stem cells to chondrocytes, and a pharmaceutical composition for treating a cartilage disease, which includes chondrocytes in which differentiation from mesenchymal stem cells is induced by the compound of Formula 1, are provided. Differentiation of the mesenchymal stem cells treated with the compound of Formula 1 to chondrocytes is specifically induced, and thus the compound can be used to effectively treat a cartilage disease such as arthritis, cartilage damage, and a cartilage defect.

  本发明提供了一种用于诱导间充质干细胞分化为软骨细胞的式1化合物的用途，以及一种用于治疗软骨疾病的药物组合物，该药物组合物包括软骨细胞，其中间充质干细胞的分化是由式1化合物诱导的。用式 1 的化合物处理的间充质干细胞特异性地被诱导分化为软骨细胞，因此该化合物可用于有效治疗关节炎、软骨损伤和软骨缺损等软骨疾病。
• Development of a Novel Class of Mitochondrial Ubiquinol–Cytochrome <i>c</i> Reductase Binding Protein (UQCRB) Modulators as Promising Antiangiogenic Leads
  作者：Hye Jin Jung、Misun Cho、Yonghyo Kim、Gyoonhee Han、Ho Jeong Kwon

  DOI：10.1021/jm500863j

  日期：2014.10.9

  Recently we identified a novel therapeutic target and small molecule for regulating angiogenesis. Our study showed that ubiquinol-cytochrome c-reductase binding protein (UQCRB) of the mitochondrial complex III plays a crucial role in hypoxia-induced angiogenesis via mitochondrial reactive oxygen species (ROS) mediated signaling. Herein, we developed new synthetic small molecules that specifically bind to UQCRB and regulate its function. To improve the pharmacological properties of 6-((1-hydroxynaphthalen 4-ylamino)dioxysulfone) 2H naphtho[1,8-bc]thiophen-2-one (HDNT), a small molecule that targets UQCRB, a series of HDNT derivatives were designed and synthesied. Several derivatives showed a significant increase in hypoxia inducible factor 1 alpha (HIF-1 alpha) inhibitory potency. compared to HDNT. The compounds bound to UQCRB and suppressed mitochondrial ROS-mediated hypoxic signaling, resulting in potent inhibitor of angiogenesis without inducing cytotoxicity. Notably, one of these new derivatives significantly suppressed tumor growth in a mouse xenograft model. Therefore, these mitochondrial UQCRB modulators could be potential leads for the development of novel antiangiogen agents.
• Novel Arylsulfoanilide−Oxindole Hybrid as an Anticancer Agent That Inhibits Translation Initiation
  作者：Amarnath Natarajan、Yuhong Guo、Frederick Harbinski、Yun-Hua Fan、Han Chen、Lia Luus、Jana Diercks、Huseyin Aktas、Michael Chorev、Jose A. Halperin

  DOI：10.1021/jm0496234

  日期：2004.10.1

  Structure-activity relationship studies of substituted arylsulfoanilides as antiproliferatives, which are mediated by the partial depletion of intracellular Ca2+ stores, resulted in the identification of compounds with micromolar activity against lung cancer cells in a growth inhibition assay. Incorporating the substitution pattern of the best arylsulfoanilides onto the 3-phenyloxindole scaffold resulted in a potent arylsulfoanilide-oxindole hybrid, 27. Compound 27 inhibits cancer cell growth by partial depletion of intracellular Ca2+ stores and phosphorylation of eIF2alpha.